Segment Information - Net Revenue and Segment Ebitda (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Net revenue		$ 1,217.0	$ 911.0	$ 2,242.0	$ 1,757.0
Inter-segment revenue elimination		(5.0)	(3.0)	(11.0)	(6.0)
Segment Reporting Information Unallocated Expense	[1]	(101.0)	(45.0)	(157.0)	(74.0)
Biologics
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Net revenue		638.0	404.0	1,184.0	781.0
Segment EBITDA		197.0	136.0	363.0	242.0
Softgel and Oral Technologies
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Net revenue		329.0	247.0	572.0	468.0
Segment EBITDA		78.0	46.0	119.0	83.0
Oral and Specialty Drug Delivery
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Net revenue		156.0	170.0	302.0	328.0
Segment EBITDA		44.0	44.0	77.0	66.0
Clinical Supply Services
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Net revenue		99.0	93.0	195.0	186.0
Segment EBITDA		27.0	25.0	53.0	50.0
Total Catalent sub-total of Segment Reporting [Member]
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Segment EBITDA		$ 346.0	$ 251.0	$ 612.0	$ 441.0

[1] Unallocated costs include restructuring and special items, stock-based compensation, gain on sale of subsidiary, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows: